Human Immunodeficiency Virus Type 1 Group M Protease in Cameroon: Genetic Diversity and Protease Inhibitor Mutational Features
Open Access
- 1 March 2002
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 40 (3), 837-845
- https://doi.org/10.1128/jcm.40.3.837-845.2002
Abstract
To establish a baseline for monitoring resistance to protease inhibitors (PIs) and examining the efficacy of their use among persons in Cameroon infected with human immunodeficiency virus type 1 (HIV-1), we analyzed genetic variability and PI resistance-associated substitutions in PCR-amplified protease (PR) sequences in strains isolated from 110 HIV-1-infected, drug-naïve Cameroonians. Of the 110 strains, 85 were classified into six HIV-1 PR subtypes, A (n = 1), B (n = 1), F (n = 4), G (n = 7), H (n = 1), and J (n = 7), and a circulating recombinant form, CRF02-AG (n = 64). PR genes from the remaining 25 (23%) specimens were unclassifiable, whereas 2% (7 of 301) unclassifiable PR sequences were reported for a global collection. Two major PI resistance-associated mutations, 20M and 24I, were detected in strains from only two specimens, whereas secondary mutations were found in strains from all samples except one strain of subtype B and two strains of CRF02-AG. The secondary mutations showed the typical PI resistance-associated pattern for non-subtype B viruses in both classifiable and unclassifiable PR genes, with 36I being the predominant (99%) mutation, followed by 63P (18%), 20R (15%), 77I (13%), and 10I or 10V (11%). Of these mutations, dual and triple PI resistance-associated substitutions were found in 38% of all the Cameroonian strains. Compared with classifiable PR sequences, unclassifiable sequences had significantly more dual and triple substitutions (64% versus 30%; P = 0.004). Phenotypic and clinical evaluations are needed to estimate whether PI resistance during antiretroviral drug treatment occurs more rapidly in individuals infected with HIV-1 strains harboring multiple PI resistance-associated substitutions. This information may be important for determination of appropriate drug therapies for HIV-1-infected persons in Cameroon, where more than one-third of HIV-1 strains were found to carry dual and triple minor PI resistance-associated mutations.Keywords
This publication has 46 references indexed in Scilit:
- Resistance to Antiretroviral Therapy Among Patients in UgandaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Presence of Diverse Human Immunodeficiency Virus Type 1 Viral Variants in CameroonAIDS Research and Human Retroviruses, 2000
- Sequence Note: Phylogenetic Analysis of Protease and Transmembrane Region of HIV Type 1 Group OAIDS Research and Human Retroviruses, 2000
- Sequence Note: Evidence of a High Frequency of HIV-1 Subtype F Infections in a Heterosexual Population in Buenos Aires, ArgentinaAIDS Research and Human Retroviruses, 2000
- Presence of Human Immunodeficiency Virus (HIV) Type 1, Group M, Non‐B Subtypes, Bronx, New York: A Sentinel Site for Monitoring HIV Genetic Diversity in the United StatesThe Journal of Infectious Diseases, 2000
- Sequence and Drug Susceptibility of Subtype C Protease from Human Immunodeficiency Virus Type 1 Seroconverters in ZimbabweAIDS Research and Human Retroviruses, 1999
- Managing Resistance to Anti-HIV DrugsDrugs, 1999
- Introduction of HIV-2 and multiple HIV-1 subtypes to Lebanon.Emerging Infectious Diseases, 1998
- The genetic data environment an expandable GUI for multiple sequence analysisBioinformatics, 1994
- Optimal alignments in linear spaceBioinformatics, 1988